Connect with us

Technology

AI in Clinical Trials Market to Reach USD 7.32 Billion by 2034 as AI Reshapes Patient Recruitment, Data Analysis and Drug Development, says Maximize Market Research

Published

on

PUNE, India, Sept. 25, 2026 /PRNewswire/ — The Global AI in Clinical Trials Market was valued at USD 2 Billion in 2025 and is projected to grow at a 15.5% CAGR from 2026 to 2034, reaching USD 7.32 Billion by 2034, according to Maximize Market Research.

Global AI in Clinical Trials Market

The Global AI in Clinical Trials Market Report 2026 provides a detailed assessment of market trends, clinical research activity, AI adoption, patient recruitment, data analysis, safety monitoring, drug discovery, personalized medicine, trial-phase applications, end-user demand, competitive developments, and market forecasts through 2034. The market is segmented by Trial Phase, Technology, Application, End-Users, and Region, covering Phase I, Phase II, and Phase III trials; machine learning, natural language processing, and deep learning; and applications including patient recruitment, data analysis, safety monitoring, drug discovery, and personalized medicine.

The market is expanding as pharmaceutical and biotechnology companies increasingly use AI to improve the speed and efficiency of clinical research. AI tools are being applied to patient screening, cohort selection, trial design, large-scale data analysis, safety evaluation, and treatment optimization. By analyzing complex patient datasets, AI can help researchers identify suitable trial participants, detect patterns more quickly, and support more targeted clinical decision-making.

Growing use of machine learning, deep learning, AI-driven patient monitoring, real-world evidence, decentralized trials, and AI-enabled drug discovery is creating new opportunities across the clinical research ecosystem. Pharmaceutical companies, CROs, hospitals, and research institutes are adopting AI to streamline workflows, improve patient recruitment, strengthen data quality, and reduce delays in drug development. These developments are expected to support the AI in Clinical Trials Market as it grows from USD 2 Billion in 2025 to USD 7.32 Billion by 2034 at a CAGR of 15.5%.

Get Full PDF Sample Copy of Report: (Including Full TOC, List of Tables & Figures, Chart) @ https://www.maximizemarketresearch.com/request-sample/222597/ 

Global AI in Clinical Trials Market gains momentum as pharmaceutical companies, CROs, and research institutions turn to AI for faster patient recruitment, smarter data analysis, improved safety monitoring, personalized medicine, and more efficient drug development, says Maximize Market Research.

Global AI in Clinical Trials Market Size & Forecast

Parameter

Value

Market Size (Base Year 2025)

USD 2 Billion

Forecast Market Size (2034)

USD 7.32 Billion

CAGR (2026-2034)

15.5 %

Base Year

2025

Forecast Period

2026-2034

Historical Period

2020-2025

Global AI in Clinical Trials Market Trends & Insights

North America leads the Global AI in Clinical Trials Market, supported by strong healthcare infrastructure, a mature pharmaceutical industry, significant investment in AI research, and increasing collaboration between pharmaceutical and technology companies. The United States remains the key regional market, while Europe is also seeing rapid adoption across the UK, Germany, and France.AI adoption is reshaping patient recruitment and clinical trial operations by helping researchers identify suitable participants, analyze large patient datasets, improve cohort selection, and support trial design. These capabilities are helping reduce delays and improve the efficiency of clinical research.Machine learning, natural language processing, and deep learning are becoming central technologies across the AI in Clinical Trials Market. Their use is expanding in patient recruitment, data analysis, safety monitoring, drug discovery, and personalized medicine across Phase I, Phase II, and Phase III trials.Pharmaceutical and biotechnology companies remain major adopters of AI in clinical research, using the technology to support drug discovery, trial execution, data analysis, and post-market surveillance. CROs, hospitals, research institutes, and government agencies are also increasing adoption as AI becomes more embedded in the clinical research ecosystem.Decentralized trials, AI-driven patient monitoring, real-world evidence, and AI-enhanced drug discovery are emerging as important market trends. Growing use of AI in diagnostics, treatment optimization, patient stratification, and personalized medicine is expected to create new opportunities as the Global AI in Clinical Trials Market advances toward 2034.

Faster Patient Recruitment and Data Analysis Drive Market Growth

The AI in Clinical Trials Market is gaining momentum as pharmaceutical companies, biotechnology firms, CROs, and research organizations look for faster and more efficient ways to manage clinical studies. AI is increasingly being used for patient screening, cohort selection, trial design, data analysis, and recruitment, helping researchers identify suitable participants and process large volumes of clinical information more quickly. These capabilities are improving trial efficiency while supporting faster drug development and better use of research resources.

Data Privacy, Regulatory Compliance, and Data Quality Restrain Adoption

Despite its potential, AI adoption in clinical trials faces important barriers. Data privacy concerns, regulatory compliance, data quality issues, and the need for specialized AI expertise can slow implementation across clinical research organizations. Because clinical trials handle sensitive patient information and operate under strict regulatory requirements, companies must ensure that AI systems are reliable, transparent, and supported by high-quality data before they can be widely integrated into trial workflows.

Decentralized Trials and AI-Driven Drug Discovery Create New Opportunities

The growing use of decentralized clinical trials, AI-driven patient monitoring, real-world evidence, and AI-enhanced drug discovery is opening new opportunities across the market. Machine learning, deep learning, and natural language processing are being applied to patient recruitment, safety monitoring, personalized medicine, and drug discovery. As AI becomes more deeply embedded in clinical research, companies have greater scope to improve trial design, identify treatment-responsive patient groups, and accelerate development of new therapies.

AI Expertise, Trust, and Reliable Clinical Data Remain Key Challenges

A major challenge for the AI in Clinical Trials Market is ensuring that AI-generated insights are supported by accurate, high-quality clinical data and can be used responsibly in regulated research environments. Organizations also need the right technical expertise to apply AI across trial phases and therapeutic areas. As AI adoption expands, maintaining data integrity, regulatory compliance, patient privacy, and confidence in AI-supported decision-making will remain central to long-term market development.

Get Insightful Data on Regions, Market Segments, Customer Landscape, and Top Companies (Charts, Tables, Figures and More) https://www.maximizemarketresearch.com/request-sample/222597/ 

Global AI in Clinical Trials Market Segmentation

The Global AI in Clinical Trials Market is segmented by Trial Phase, Technology, Application, End-Users, and Region. The market covers AI adoption across Phase I, Phase II, and Phase III clinical trials, with technologies such as machine learning, natural language processing, and deep learning supporting patient recruitment, data analysis, safety monitoring, drug discovery, and personalized medicine. Pharmaceutical companies, research institutes, CROs, hospitals, and other end-users are increasingly integrating AI into clinical research workflows.

Segmentation

Sub-Segments

By Trial Phase

Phase I; Phase II; Phase III

By Technology

Machine Learning; Natural Language Processing; Deep Learning; Unspecified

By Application

Patient Recruitment; Data Analysis; Safety Monitoring; Drug Discovery; Personalized Medicine

By End-Users

Pharmaceutical Companies; Research Institutes; CRO’s; Hospitals; Others

By Region

North America; Europe; Asia Pacific; Middle East & Africa; South America

North America Leads the AI in Clinical Trials Market as Asia Pacific Gains Ground

North America leads the Global AI in Clinical Trials Market, supported by advanced healthcare infrastructure, a well-established pharmaceutical industry, strong investment in AI research, and growing collaboration between drug developers and technology companies. The United States remains the key market as AI is increasingly used for patient recruitment, data analysis, safety monitoring, drug discovery, and personalized medicine.

Europe is also seeing steady adoption of AI in clinical research, particularly across the UK, Germany, and France. Strong pharmaceutical capabilities, established regulatory systems, government support for healthcare AI, and cross-border research partnerships are helping expand the use of machine learning and digital technologies in clinical trials.

Asia Pacific is emerging as an important market, led by China, India, and Japan. Large patient populations, expanding pharmaceutical sectors, and growing interest in more efficient and affordable clinical research are encouraging wider adoption of AI. Japan’s advanced technology ecosystem is also creating opportunities for AI-driven healthcare and clinical trial applications.

South America and the Middle East & Africa remain developing markets for AI in Clinical Trials. Expanding pharmaceutical activity, improving healthcare infrastructure, evolving regulatory frameworks, and partnerships with international research and pharmaceutical organizations are supporting gradual adoption across these regions.

Leading Companies Expand the AI in Clinical Trials Market

Euretos, Biosymetrics, Unlearn.AI, Exscientia, AiCure, Antidote Technologies, Deep 6 AI, Innoplexus, IQVIA, Medidata, Mendel.ai, Phesi, Saama Technologies, Signant Health, Trials.ai, and other participants are active across the AI in Clinical Trials Market. These companies are developing solutions for patient recruitment, clinical data analysis, trial optimization, safety monitoring, and AI-supported drug development.

Global AI in Clinical Trials Market Competitive Landscape

Competition in the Global AI in Clinical Trials Market is becoming more technology-driven as companies focus on machine learning, deep learning, natural language processing, AI-powered patient recruitment, predictive analytics, and personalized medicine. Partnerships between pharmaceutical companies, research institutions, and AI technology providers are also becoming increasingly important in accelerating clinical research.

The market is also being shaped by decentralized trials, AI-driven patient monitoring, real-world evidence, and AI-enhanced drug discovery. Companies that can improve trial efficiency, shorten recruitment timelines, strengthen data analysis, and support better treatment decisions are likely to gain greater relevance as AI adoption expands across clinical research through 2034.

Immediate Delivery Available | Buy this Research Report (Insights, Charts, Tables, Figures and More) https://www.maximizemarketresearch.com/checkout/222597/ 

Key Players of the AI in Clinical Trials Market

EuretosBiosymetricUnlearn.AI,Inc.ExscientiaIMB CorporationAiCureAntidote TechnologiesDeep 6 AIInnoplexusIQVIAMedian TechnologiesMedidataMendel.aiPhesiSaama TechnologiesSignant HealthTrials.ai

Frequently Asked Questions and Answers about AI in Clinical Trials Market

1. How AI can improve clinical trials?
Ans: AI can improve clinical trials by expediting patient recruitment, enhancing data analysis accuracy, personalizing treatment plans, and optimizing trial designs.

2. What are the challenges associated with the integration of AI in clinical trials?
Ans: Challenges associated with integrating AI in clinical trials include data privacy concerns, regulatory compliance, data quality, and the need for AI expertise.

3. What is the role of AI in electronic health records of clinical trials data?
Ans: AI plays a role in electronic health records of clinical trials data by facilitating data management, analysis, and insights for more efficient and informed decision-making.

4. What are the upcoming trends in AI in clinical trial market?
Ans: Upcoming trends in the AI in clinical trial market include decentralized trials, AI-driven patient monitoring, real-world evidence utilization, and AI-enhanced drug discovery.

5. Which region captures the largest share in the AI in clinical trials market?
Ans: North America captures the largest share in the AI in clinical trials market, driven by its robust healthcare infrastructure and significant investments in AI research.

Access Full Summary: https://www.maximizemarketresearch.com/market-report/ai-in-clinical-trials-market/222597/ 

Analyst Perspective

Analysts note that the Global AI in Clinical Trials Market is being driven by the growing use of AI to improve patient recruitment, clinical data analysis, safety monitoring, drug discovery, and personalized medicine. Pharmaceutical companies, CROs, hospitals, and research institutes are increasingly adopting machine learning, deep learning, and other AI tools to make clinical trials faster and more efficient. Data privacy, regulatory compliance, data quality, and the need for specialized AI expertise remain important challenges, while decentralized trials, AI-driven patient monitoring, real-world evidence, and AI-enabled drug discovery are expected to create new opportunities through 2034.

Related Reports:

Clinical Trial Management Systems Market by Type, Component, Delivery Mode, End User, and Region – Global Forecast to 2034

Healthcare Artificial Intelligence Market by Component, Application, End-User, and Region – Global Forecast to 2034

Clinical Trial Imaging Market by Product and Service, Modality, Application, End Users, and Region – Global Forecast to 2034

Healthcare Analytics Market by Type, Component, Delivery Mode, Application, End-User, and Region – Global Forecast to 2034

Healthcare Big Data Analytics Market by Type, Application, Component, Deployment Model, End User, and Region – Global Forecast to 2034

About Maximize Market Research – Global AI in Clinical Trials Market

Maximize Market Research is a global market research and business consulting firm providing data-driven insights across Healthcare, Pharmaceuticals, Biotechnology, Life Sciences, Clinical Research, and Artificial Intelligence, including the Global AI in Clinical Trials Market. Its research helps businesses understand market dynamics, technology adoption, regulatory developments, competitive activity, and emerging opportunities across patient recruitment, data analysis, safety monitoring, drug discovery, personalized medicine, and AI-enabled clinical research.

Expertise in AI in Clinical Trials & Healthcare Research

Maximize Market Research provides insights across Healthcare, clinical trials, pharmaceutical R&D, biotechnology, and AI-driven medical technologies. Its research covers machine learning, natural language processing, deep learning, AI-powered patient recruitment, clinical data analysis, safety monitoring, drug discovery, personalized medicine, decentralized trials, real-world evidence, and AI-based patient monitoring. The research also evaluates adoption trends across pharmaceutical companies, CROs, hospitals, and research institutes, along with regional and competitive developments shaping the AI in Clinical Trials Market.

Contact:
Lumawant Godage
MAXIMIZE MARKET RESEARCH PVT. LTD.
+91 96073 65656
Email: sales@maximizemarketresearch.com
Content Source: https://www.maximizemarketresearch.com/market-report/ai-in-clinical-trials-market/222597/
Visit Our Web Site: https://www.maximizemarketresearch.com/ 
LinkedIn.com: https://www.linkedin.com/company/maxmize-market-research-pvt-ltd/
Instagram: https://www.instagram.com/maximizemarketresearch/
Facebook: https://www.facebook.com/maximizemarketresearch/ 
X (Twitter): https://x.com/MMRAnalytics

 

View original content to download multimedia:https://www.prnewswire.co.uk/news-releases/ai-in-clinical-trials-market-to-reach-usd-7-32-billion-by-2034-as-ai-reshapes-patient-recruitment-data-analysis-and-drug-development-says-maximize-market-research-302890253.html

Continue Reading

Technology

Sabre Corporation Announces Early Tender Results of Previously Announced Cash Tender Offer and Consent Solicitation by Sabre Financial Borrower, LLC

Published

on

By

SOUTHLAKE, Texas, Sept. 25, 2026 /PRNewswire/ — Sabre Corporation (“Sabre”) (Nasdaq: SABR) today announced the early tender results of the previously announced cash tender offer (the “Tender Offer”) by Sabre Financial Borrower, LLC (“Sabre Financial”), its indirect wholly-owned subsidiary, for any and all of Sabre Financial’s securities set forth in the table below (the “Securities”) and concurrent solicitation of consents (the “Consent Solicitation”) to certain proposed amendments to the Securities and the Indenture (as defined below). The Tender Offer and Consent Solicitation will expire at 5:00 p.m., New York City time, on October 12, 2026 (unless extended or earlier terminated, the “Expiration Date”).

The Tender Offer and Consent Solicitation are being made pursuant to the terms and conditions set forth in the offer to purchase and consent solicitation statement, dated September 14, 2026 (the “Offer to Purchase”).

As of 5:00 p.m., New York City time, on September 25, 2026 (such date and time, the “Early Tender Deadline” and “Withdrawal Deadline,” as applicable), according to information provided to D.F. King & Co., Inc., the tender and information agent for the Tender Offer and Consent Solicitation, the aggregate principal amount of Securities listed in the table below has been validly tendered and not validly withdrawn in the Tender Offer and Consent Solicitation. Withdrawal rights for the Securities expired at the Early Tender Deadline and, accordingly, any Securities that were validly tendered may no longer be withdrawn except where additional withdrawal rights are required by law.

Title of

Security

CUSIP / ISIN Number

Principal

Amount 

Outstanding

Principal Amount

Tendered at Early

Tender Deadline

Percentage of

Outstanding

Securities Tendered

Total

Consideration

(1)(2)

11.125% Senior

Secured Notes 

due 2029

78573X AA8

U86042 AA3

US78573XAA81

USU86042AA34

$1,000,000,000.00

$ 930,682,000.00

93.07 %

$        $1,092.50

 

(1)

Dollars per $1,000 principal amount of Securities validly tendered and accepted for purchase.

(2)

Includes Early Tender Premium (as defined below). Does not include accrued and unpaid interest on the Securities, which will also be payable as provided herein.

The Tender Offer and Consent Solicitation remain subject to the satisfaction or waiver of the conditions described in the Offer to Purchase, including the financing for the Tender Offer and Consent Solicitation. Such conditions may be waived by Sabre Financial in its sole discretion, subject to applicable law. Any waiver of a condition by Sabre Financial will not constitute a waiver of any other condition. Subject to the satisfaction or waiver of such conditions and as described in the Offer to Purchase, Sabre Financial is expected to make payment on September 28, 2026 (such date and time, as it may be extended, the “Early Settlement Date”) for the Securities and related consents that (i) were validly tendered and delivered, as applicable, and not validly withdrawn or revoked, as applicable, at or prior to the Early Tender Deadline and (ii) are accepted for purchase on the Early Settlement Date.

The consideration to be paid for the Securities accepted for purchase on the Early Settlement Date per $1,000 principal amount of Securities is the amount set forth in the table above under the heading “Total Consideration.” The amounts set forth in the table above under “Total Consideration” include an early tender premium of $50 per $1,000 principal amount of Securities accepted for purchase (the “Early Tender Premium”). All Holders of Securities accepted for purchase will also receive accrued and unpaid interest from the most recent interest payment date preceding the Early Settlement Date to, but not including, the Early Settlement Date.

Any Holder who tenders Securities in the Tender Offer and Consent Solicitation will be deemed to automatically have provided consents, and Securities may not be tendered without delivering consents. Based on the consents received as of the Early Tender Deadline, Sabre Financial has obtained the required consents to effect all of the proposed amendments (the “Proposed Amendments”) as described in the Offer to Purchase. Consequently, as previously announced, Sabre Financial expects to execute a supplemental indenture (the “Supplemental Indenture”) effecting the Proposed Amendments with respect to the indenture dated December 5, 2025 (the “Indenture”), entered into by and among Sabre Financial, the guarantors party thereto, and Wilmington Trust, National Association, as trustee and collateral agent, under which the Securities were issued, and the Securities on or about the Early Settlement Date. The Supplemental Indenture will become effective upon (a) its execution and delivery by each of the parties thereto, and (b) the settlement of the Tender Offer with respect to accepted Securities tendered prior to the Early Tender Deadline on the Early Settlement Date.

In addition, pursuant to the terms of the Indenture, because more than 90% of the aggregate principal amount of the Securities outstanding has been validly tendered in the Tender Offer, Sabre Financial intends, following its purchase of the tendered Securities, to deliver a notice of redemption to redeem all Securities that remain outstanding after giving effect to the purchase of the Securities on the Early Settlement Date. The redemption price for such Securities will be equal to the Total Consideration set forth in the table above, plus accrued and unpaid interest thereon to, but excluding, the redemption date. The redemption date is expected to be October 13, 2026. Notwithstanding the foregoing, there can be no assurance that any Securities will be redeemed. Nothing herein shall constitute a notice of redemption with respect to the Securities.

Sabre Financial reserves the right, subject to applicable law, in its sole discretion, to waive any of the conditions of the Tender Offer or the Consent Solicitation, in whole or in part, at any time and from time to time. It also reserves the right, subject to applicable law, in its sole discretion, (1) to terminate or withdraw the Tender Offer or the Consent Solicitation at any time; (2) to extend the Early Tender Deadline, the Withdrawal Deadline or the Expiration Date; or (3) otherwise to amend the Tender Offer or Consent Solicitation in any respect. It may extend the Early Tender Deadline without extending the Withdrawal Deadline.

Information Relating to the Tender Offer and Consent Solicitation

The complete terms and conditions of the Tender Offer and Consent Solicitation are set forth in the Offer to Purchase. BofA Securities is the Dealer Manager and Solicitation Agent for the Tender Offer and Consent Solicitation. Investors with questions regarding the Tender Offer and Consent Solicitation may contact BofA Securities, collect: (980) 388-3646, toll-free: (888) 292-0070, email: debt_advisory@bofa.com. D.F. King & Co., Inc. is the tender and information agent for the Tender Offer and Consent Solicitation. Copies of the Offer to Purchase and any related offer documents may be obtained by contacting D.F. King & Co., Inc. by phone at (646) 455-1060 (New York) or (866) 356-7814 (toll-free) or by email at sabre@dfking.com. 

None of Sabre Financial, Sabre, their affiliates, their respective boards of directors and stockholders, the Dealer Manager and Solicitation Agent, the Tender Agent or Wilmington Trust, National Association, as trustee for the Securities, are making any recommendation as to whether Holders should tender any Securities or deliver any Consent in response to the Tender Offer and Consent Solicitation. Holders must make their own decision as to whether to tender any of their Securities and deliver their Consents, and, if so, the principal amount of Securities to tender and Consents to deliver.

This press release is for informational purposes only and is not an offer to buy or a solicitation of an offer to sell any of the Securities, and the Tender Offer and Consent Solicitation do not constitute offers to buy or the solicitation of offers to sell Securities in any jurisdiction or in any circumstances in which such offers are unlawful. The full details of the Tender Offer and Consent Solicitation, including complete instructions on how to tender Securities and deliver Consents, are included in the Offer to Purchase. Holders are strongly encouraged to read carefully the Offer to Purchase because it will contain important information.

Forward-Looking Statements

Certain statements herein are forward-looking statements about trends, future events, uncertainties and our plans and expectations of what may happen in the future. Any statements that are not historical or current facts are forward-looking statements. In many cases, you can identify forward-looking statements by terms such as “expect,” “guidance,” “outlook,” “trend,” “pro forma,” “on course,” “on track,” “target,” “potential,” “benefit,” “goal,” “believe,” “plan,” “confident,” “anticipate,” “indicate,” “trend,” “position,” “optimistic,” “will,” “forecast,” “continue,” “strategy,” “estimate,” “project,” “may,” “should,” “would,” “intend,” or the negative of these terms, where applicable, or other comparable terminology. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performances or achievements expressed or implied by the forward-looking statements. More information about potential risks and uncertainties that could materially affect our business and results of operations is included in the “Risk Factors” and “Forward-Looking Statements” sections in our Quarterly Report on Form 10-Q for the quarter ended June 30, 2026, filed with the SEC on August 6, 2026, our Annual Report on Form 10-K for the year ended December 31, 2025, filed with the SEC on February 18, 2026 and in our other filings with the SEC, as well as other risks and uncertainties specified in the “Certain Significant Considerations” section of the Offer to Purchase. We cannot guarantee future events, including financing of the Tender Offer and Consent Solicitation and successful completion of the Tender Offer and Consent Solicitation, outlook, guidance, results, actions, levels of activity, performance or achievements. Readers are cautioned not to place undue reliance on these forward-looking statements. Unless required by law, we undertake no obligation to publicly update or revise any forward-looking statements to reflect circumstances or events after the date they are made.

About Sabre

Powering the agentic revolution in travel. Sabre is an AI-native technology leader, backed by one of the world’s largest travel data clouds. With AI at its core and operating at unparalleled scale, Sabre transforms insights into innovation, empowering airlines, hoteliers, agencies and other partners to retail, distribute and fulfill travel worldwide. Sabre is built on an open, modular, cloud-native architecture and serves as the backbone for both established leaders and bold, new disruptors, guiding them to the next age of travel retailing through intelligent, connected, and personalized experiences.  

SABR-F

Contacts:

 

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/sabre-corporation-announces-early-tender-results-of-previously-announced-cash-tender-offer-and-consent-solicitation-by-sabre-financial-borrower-llc-302890677.html

SOURCE Sabre Corporation

Continue Reading

Technology

ATB Investment Management announces U.S. equity sub-advisor transition for Compass Portfolios and ATBIS U.S. Equity Pool

Published

on

By

EDMONTON, AB, Sept. 25, 2026 /CNW/ — ATB Investment Management Inc. today announced a sub-advisor transition to Boston Partners Global Investors, Inc.’s U.S. Large Cap Value Equity Strategy for the following funds (the “Funds”) from the Funds’ existing U.S. equities sub-advisor effective on or about October 15, 2026:

Compass Conservative PortfolioCompass Conservative Balanced PortfolioCompass Balanced PortfolioCompass Balanced Growth PortfolioCompass Growth PortfolioCompass Maximum Growth PortfolioATBIS U.S. Equity Pool

There are no changes to the investment objectives or investment strategies of the Funds.

Boston Partners Global Investors, Inc. (“Boston Partners”) is an institutional investment manager specializing in global value-equity strategies. Their clients include corporate and public pension plans, endowments, foundations, and high-net-worth individuals across major global markets. Boston Partners offers investment capabilities across U.S. and global and Non-US equities, long/short equities, and private wealth solutions. Boston Partners consists of 190 employees headquartered in Boston, with four other offices around the world. The firm manages nearly $150 billion USD as of June 30, 2026.

On September 28, 2026 a special distribution will be paid to unitholders with a record date of September 25, 2026, in relation to the appointment of Boston Partners. Information about the special distribution will be available on the ATB Investment Management website, at atbim.atb.com, on September 29, 2026.

About ATB Investment Management Inc.
ATB Investment Management Inc. (ATBIM), the asset management subsidiary of ATB Financial, provides a range of high-quality comprehensive investment management services and solutions. ATBIM’s offerings include: a range of mutual funds, including the Compass Portfolios, and tailored discretionary investment management for high-net-worth individuals and institutions. Established over 20 years ago and with over $25.2 billion in assets under management, ATBIM provides trusted expertise and a commitment to client success.

ATBIM is registered as a Portfolio Manager across various Canadian securities commissions with the Alberta Securities Commission (ASC) being its principal regulator. ATBIM is also registered as an Investment Fund Manager who manages the ATB Funds. ATBIM is a wholly owned subsidiary of ATB Financial and is a licensed user of the registered trademark ATB Wealth.

Commissions, trailing commissions, management fees and expenses all may be associated with mutual fund investments. Please read the prospectus before investing. Mutual funds are not guaranteed, their values change frequently and past performance may not be repeated.

About ATB Financial
Powering possibilities for our clients, communities, and beyond is what drives us at ATB Financial. As a leading Alberta-based financial institution with over $115 billion in total assets and assets under management, our success comes from more than 5,400 team members who deliver exceptional experiences to over 855,000 clients across our Personal and Business Banking, ATB Wealth Management, and ATB Cormark Capital Markets businesses. ATB Financial provides expert advice and services through our extensive branch network and agencies, our dedicated Client Care Centre and our digital banking options. ATB Financial is bronze certified as part of the Partnership Accreditation in Indigenous Relations commissioned by the Canadian Council for Indigenous Business. More information about ATB can be found at atb.com.

For more information or interview requests, please contact:
ATB Financial, Media Relations Team media@atb.com

SOURCE ATB Financial

Continue Reading

Technology

CGTN AMERICA & CCTV UN: Peng Liyuan, Melania Trump Visit National Museum of Asian Art

Published

on

By

Peng Liyuan, wife of Chinese President Xi Jinping, and Melania Trump, wife of US President Donald Trump, visited the National Museum of Asian Art in Washington, D.C., on Thursday, September 24.

WASHINGTON, Sept. 25, 2026 /PRNewswire-PRWeb/ — (This material is distributed by MediaLinks TV, LLC on behalf of CCTV. Additional information is available at the Department of Justice, Washington, D.C.)

CGTN America & CCTV UN releases “Peng Liyuan, Melania Trump Visit National Museum of Asian Art”

Peng Liyuan, wife of Chinese President Xi Jinping, and Melania Trump, wife of US President Donald Trump, visited the National Museum of Asian Art in Washington, D.C., on Thursday, September 24.

Peng and Melania visited exhibition halls including the Peacock Room. Peng expressed appreciation for the US side’s return of Chinese cultural relics to China on multiple occasions in recent years, expressing hope that China and the United States would continue to strengthen cooperation on cultural exchanges and cultural heritage protection and deepen the friendship between the two peoples.

After the tour, Peng and Melania watched American teenagers sing Chinese songs together and had cordial exchanges with them. Peng encouraged them to continue studying the Chinese language and culture and to become envoys of friendship between China and the United States.

The National Museum of Asian Art is a renowned US institution dedicated to the collection, research and exhibition of Asian art.

Media Contact

Sun, CGTN America, 1 2023931850, distribution@cgtnamerica.com

View original content:https://www.prweb.com/releases/cgtn-america–cctv-un-peng-liyuan-melania-trump-visit-national-museum-of-asian-art-302890609.html

SOURCE CGTN America

Continue Reading

Trending

Technology

AI in Clinical Trials Market to Reach USD 7.32 Billion by 2034 as AI Reshapes Patient Recruitment, Data Analysis and Drug Development, says Maximize Market Research

Published

on

PUNE, India, Sept. 25, 2026 /PRNewswire/ — The Global AI in Clinical Trials Market was valued at USD 2 Billion in 2025 and is projected to grow at a 15.5% CAGR from 2026 to 2034, reaching USD 7.32 Billion by 2034, according to Maximize Market Research.

Global AI in Clinical Trials Market

The Global AI in Clinical Trials Market Report 2026 provides a detailed assessment of market trends, clinical research activity, AI adoption, patient recruitment, data analysis, safety monitoring, drug discovery, personalized medicine, trial-phase applications, end-user demand, competitive developments, and market forecasts through 2034. The market is segmented by Trial Phase, Technology, Application, End-Users, and Region, covering Phase I, Phase II, and Phase III trials; machine learning, natural language processing, and deep learning; and applications including patient recruitment, data analysis, safety monitoring, drug discovery, and personalized medicine.

The market is expanding as pharmaceutical and biotechnology companies increasingly use AI to improve the speed and efficiency of clinical research. AI tools are being applied to patient screening, cohort selection, trial design, large-scale data analysis, safety evaluation, and treatment optimization. By analyzing complex patient datasets, AI can help researchers identify suitable trial participants, detect patterns more quickly, and support more targeted clinical decision-making.

Growing use of machine learning, deep learning, AI-driven patient monitoring, real-world evidence, decentralized trials, and AI-enabled drug discovery is creating new opportunities across the clinical research ecosystem. Pharmaceutical companies, CROs, hospitals, and research institutes are adopting AI to streamline workflows, improve patient recruitment, strengthen data quality, and reduce delays in drug development. These developments are expected to support the AI in Clinical Trials Market as it grows from USD 2 Billion in 2025 to USD 7.32 Billion by 2034 at a CAGR of 15.5%.

Get Full PDF Sample Copy of Report: (Including Full TOC, List of Tables & Figures, Chart) @ https://www.maximizemarketresearch.com/request-sample/222597/ 

Global AI in Clinical Trials Market gains momentum as pharmaceutical companies, CROs, and research institutions turn to AI for faster patient recruitment, smarter data analysis, improved safety monitoring, personalized medicine, and more efficient drug development, says Maximize Market Research.

Global AI in Clinical Trials Market Size & Forecast

Parameter

Value

Market Size (Base Year 2025)

USD 2 Billion

Forecast Market Size (2034)

USD 7.32 Billion

CAGR (2026-2034)

15.5 %

Base Year

2025

Forecast Period

2026-2034

Historical Period

2020-2025

Global AI in Clinical Trials Market Trends & Insights

North America leads the Global AI in Clinical Trials Market, supported by strong healthcare infrastructure, a mature pharmaceutical industry, significant investment in AI research, and increasing collaboration between pharmaceutical and technology companies. The United States remains the key regional market, while Europe is also seeing rapid adoption across the UK, Germany, and France.AI adoption is reshaping patient recruitment and clinical trial operations by helping researchers identify suitable participants, analyze large patient datasets, improve cohort selection, and support trial design. These capabilities are helping reduce delays and improve the efficiency of clinical research.Machine learning, natural language processing, and deep learning are becoming central technologies across the AI in Clinical Trials Market. Their use is expanding in patient recruitment, data analysis, safety monitoring, drug discovery, and personalized medicine across Phase I, Phase II, and Phase III trials.Pharmaceutical and biotechnology companies remain major adopters of AI in clinical research, using the technology to support drug discovery, trial execution, data analysis, and post-market surveillance. CROs, hospitals, research institutes, and government agencies are also increasing adoption as AI becomes more embedded in the clinical research ecosystem.Decentralized trials, AI-driven patient monitoring, real-world evidence, and AI-enhanced drug discovery are emerging as important market trends. Growing use of AI in diagnostics, treatment optimization, patient stratification, and personalized medicine is expected to create new opportunities as the Global AI in Clinical Trials Market advances toward 2034.

Faster Patient Recruitment and Data Analysis Drive Market Growth

The AI in Clinical Trials Market is gaining momentum as pharmaceutical companies, biotechnology firms, CROs, and research organizations look for faster and more efficient ways to manage clinical studies. AI is increasingly being used for patient screening, cohort selection, trial design, data analysis, and recruitment, helping researchers identify suitable participants and process large volumes of clinical information more quickly. These capabilities are improving trial efficiency while supporting faster drug development and better use of research resources.

Data Privacy, Regulatory Compliance, and Data Quality Restrain Adoption

Despite its potential, AI adoption in clinical trials faces important barriers. Data privacy concerns, regulatory compliance, data quality issues, and the need for specialized AI expertise can slow implementation across clinical research organizations. Because clinical trials handle sensitive patient information and operate under strict regulatory requirements, companies must ensure that AI systems are reliable, transparent, and supported by high-quality data before they can be widely integrated into trial workflows.

Decentralized Trials and AI-Driven Drug Discovery Create New Opportunities

The growing use of decentralized clinical trials, AI-driven patient monitoring, real-world evidence, and AI-enhanced drug discovery is opening new opportunities across the market. Machine learning, deep learning, and natural language processing are being applied to patient recruitment, safety monitoring, personalized medicine, and drug discovery. As AI becomes more deeply embedded in clinical research, companies have greater scope to improve trial design, identify treatment-responsive patient groups, and accelerate development of new therapies.

AI Expertise, Trust, and Reliable Clinical Data Remain Key Challenges

A major challenge for the AI in Clinical Trials Market is ensuring that AI-generated insights are supported by accurate, high-quality clinical data and can be used responsibly in regulated research environments. Organizations also need the right technical expertise to apply AI across trial phases and therapeutic areas. As AI adoption expands, maintaining data integrity, regulatory compliance, patient privacy, and confidence in AI-supported decision-making will remain central to long-term market development.

Get Insightful Data on Regions, Market Segments, Customer Landscape, and Top Companies (Charts, Tables, Figures and More) https://www.maximizemarketresearch.com/request-sample/222597/ 

Global AI in Clinical Trials Market Segmentation

The Global AI in Clinical Trials Market is segmented by Trial Phase, Technology, Application, End-Users, and Region. The market covers AI adoption across Phase I, Phase II, and Phase III clinical trials, with technologies such as machine learning, natural language processing, and deep learning supporting patient recruitment, data analysis, safety monitoring, drug discovery, and personalized medicine. Pharmaceutical companies, research institutes, CROs, hospitals, and other end-users are increasingly integrating AI into clinical research workflows.

Segmentation

Sub-Segments

By Trial Phase

Phase I; Phase II; Phase III

By Technology

Machine Learning; Natural Language Processing; Deep Learning; Unspecified

By Application

Patient Recruitment; Data Analysis; Safety Monitoring; Drug Discovery; Personalized Medicine

By End-Users

Pharmaceutical Companies; Research Institutes; CRO’s; Hospitals; Others

By Region

North America; Europe; Asia Pacific; Middle East & Africa; South America

North America Leads the AI in Clinical Trials Market as Asia Pacific Gains Ground

North America leads the Global AI in Clinical Trials Market, supported by advanced healthcare infrastructure, a well-established pharmaceutical industry, strong investment in AI research, and growing collaboration between drug developers and technology companies. The United States remains the key market as AI is increasingly used for patient recruitment, data analysis, safety monitoring, drug discovery, and personalized medicine.

Europe is also seeing steady adoption of AI in clinical research, particularly across the UK, Germany, and France. Strong pharmaceutical capabilities, established regulatory systems, government support for healthcare AI, and cross-border research partnerships are helping expand the use of machine learning and digital technologies in clinical trials.

Asia Pacific is emerging as an important market, led by China, India, and Japan. Large patient populations, expanding pharmaceutical sectors, and growing interest in more efficient and affordable clinical research are encouraging wider adoption of AI. Japan’s advanced technology ecosystem is also creating opportunities for AI-driven healthcare and clinical trial applications.

South America and the Middle East & Africa remain developing markets for AI in Clinical Trials. Expanding pharmaceutical activity, improving healthcare infrastructure, evolving regulatory frameworks, and partnerships with international research and pharmaceutical organizations are supporting gradual adoption across these regions.

Leading Companies Expand the AI in Clinical Trials Market

Euretos, Biosymetrics, Unlearn.AI, Exscientia, AiCure, Antidote Technologies, Deep 6 AI, Innoplexus, IQVIA, Medidata, Mendel.ai, Phesi, Saama Technologies, Signant Health, Trials.ai, and other participants are active across the AI in Clinical Trials Market. These companies are developing solutions for patient recruitment, clinical data analysis, trial optimization, safety monitoring, and AI-supported drug development.

Global AI in Clinical Trials Market Competitive Landscape

Competition in the Global AI in Clinical Trials Market is becoming more technology-driven as companies focus on machine learning, deep learning, natural language processing, AI-powered patient recruitment, predictive analytics, and personalized medicine. Partnerships between pharmaceutical companies, research institutions, and AI technology providers are also becoming increasingly important in accelerating clinical research.

The market is also being shaped by decentralized trials, AI-driven patient monitoring, real-world evidence, and AI-enhanced drug discovery. Companies that can improve trial efficiency, shorten recruitment timelines, strengthen data analysis, and support better treatment decisions are likely to gain greater relevance as AI adoption expands across clinical research through 2034.

Immediate Delivery Available | Buy this Research Report (Insights, Charts, Tables, Figures and More) https://www.maximizemarketresearch.com/checkout/222597/ 

Key Players of the AI in Clinical Trials Market

EuretosBiosymetricUnlearn.AI,Inc.ExscientiaIMB CorporationAiCureAntidote TechnologiesDeep 6 AIInnoplexusIQVIAMedian TechnologiesMedidataMendel.aiPhesiSaama TechnologiesSignant HealthTrials.ai

Frequently Asked Questions and Answers about AI in Clinical Trials Market

1. How AI can improve clinical trials?
Ans: AI can improve clinical trials by expediting patient recruitment, enhancing data analysis accuracy, personalizing treatment plans, and optimizing trial designs.

2. What are the challenges associated with the integration of AI in clinical trials?
Ans: Challenges associated with integrating AI in clinical trials include data privacy concerns, regulatory compliance, data quality, and the need for AI expertise.

3. What is the role of AI in electronic health records of clinical trials data?
Ans: AI plays a role in electronic health records of clinical trials data by facilitating data management, analysis, and insights for more efficient and informed decision-making.

4. What are the upcoming trends in AI in clinical trial market?
Ans: Upcoming trends in the AI in clinical trial market include decentralized trials, AI-driven patient monitoring, real-world evidence utilization, and AI-enhanced drug discovery.

5. Which region captures the largest share in the AI in clinical trials market?
Ans: North America captures the largest share in the AI in clinical trials market, driven by its robust healthcare infrastructure and significant investments in AI research.

Access Full Summary: https://www.maximizemarketresearch.com/market-report/ai-in-clinical-trials-market/222597/ 

Analyst Perspective

Analysts note that the Global AI in Clinical Trials Market is being driven by the growing use of AI to improve patient recruitment, clinical data analysis, safety monitoring, drug discovery, and personalized medicine. Pharmaceutical companies, CROs, hospitals, and research institutes are increasingly adopting machine learning, deep learning, and other AI tools to make clinical trials faster and more efficient. Data privacy, regulatory compliance, data quality, and the need for specialized AI expertise remain important challenges, while decentralized trials, AI-driven patient monitoring, real-world evidence, and AI-enabled drug discovery are expected to create new opportunities through 2034.

Related Reports:

Clinical Trial Management Systems Market by Type, Component, Delivery Mode, End User, and Region – Global Forecast to 2034

Healthcare Artificial Intelligence Market by Component, Application, End-User, and Region – Global Forecast to 2034

Clinical Trial Imaging Market by Product and Service, Modality, Application, End Users, and Region – Global Forecast to 2034

Healthcare Analytics Market by Type, Component, Delivery Mode, Application, End-User, and Region – Global Forecast to 2034

Healthcare Big Data Analytics Market by Type, Application, Component, Deployment Model, End User, and Region – Global Forecast to 2034

About Maximize Market Research – Global AI in Clinical Trials Market

Maximize Market Research is a global market research and business consulting firm providing data-driven insights across Healthcare, Pharmaceuticals, Biotechnology, Life Sciences, Clinical Research, and Artificial Intelligence, including the Global AI in Clinical Trials Market. Its research helps businesses understand market dynamics, technology adoption, regulatory developments, competitive activity, and emerging opportunities across patient recruitment, data analysis, safety monitoring, drug discovery, personalized medicine, and AI-enabled clinical research.

Expertise in AI in Clinical Trials & Healthcare Research

Maximize Market Research provides insights across Healthcare, clinical trials, pharmaceutical R&D, biotechnology, and AI-driven medical technologies. Its research covers machine learning, natural language processing, deep learning, AI-powered patient recruitment, clinical data analysis, safety monitoring, drug discovery, personalized medicine, decentralized trials, real-world evidence, and AI-based patient monitoring. The research also evaluates adoption trends across pharmaceutical companies, CROs, hospitals, and research institutes, along with regional and competitive developments shaping the AI in Clinical Trials Market.

Contact:
Lumawant Godage
MAXIMIZE MARKET RESEARCH PVT. LTD.
+91 96073 65656
Email: sales@maximizemarketresearch.com
Content Source: https://www.maximizemarketresearch.com/market-report/ai-in-clinical-trials-market/222597/
Visit Our Web Site: https://www.maximizemarketresearch.com/ 
LinkedIn.com: https://www.linkedin.com/company/maxmize-market-research-pvt-ltd/
Instagram: https://www.instagram.com/maximizemarketresearch/
Facebook: https://www.facebook.com/maximizemarketresearch/ 
X (Twitter): https://x.com/MMRAnalytics

 

View original content to download multimedia:https://www.prnewswire.co.uk/news-releases/ai-in-clinical-trials-market-to-reach-usd-7-32-billion-by-2034-as-ai-reshapes-patient-recruitment-data-analysis-and-drug-development-says-maximize-market-research-302890253.html

Continue Reading

Technology

Sabre Corporation Announces Early Tender Results of Previously Announced Cash Tender Offer and Consent Solicitation by Sabre Financial Borrower, LLC

Published

on

By

SOUTHLAKE, Texas, Sept. 25, 2026 /PRNewswire/ — Sabre Corporation (“Sabre”) (Nasdaq: SABR) today announced the early tender results of the previously announced cash tender offer (the “Tender Offer”) by Sabre Financial Borrower, LLC (“Sabre Financial”), its indirect wholly-owned subsidiary, for any and all of Sabre Financial’s securities set forth in the table below (the “Securities”) and concurrent solicitation of consents (the “Consent Solicitation”) to certain proposed amendments to the Securities and the Indenture (as defined below). The Tender Offer and Consent Solicitation will expire at 5:00 p.m., New York City time, on October 12, 2026 (unless extended or earlier terminated, the “Expiration Date”).

The Tender Offer and Consent Solicitation are being made pursuant to the terms and conditions set forth in the offer to purchase and consent solicitation statement, dated September 14, 2026 (the “Offer to Purchase”).

As of 5:00 p.m., New York City time, on September 25, 2026 (such date and time, the “Early Tender Deadline” and “Withdrawal Deadline,” as applicable), according to information provided to D.F. King & Co., Inc., the tender and information agent for the Tender Offer and Consent Solicitation, the aggregate principal amount of Securities listed in the table below has been validly tendered and not validly withdrawn in the Tender Offer and Consent Solicitation. Withdrawal rights for the Securities expired at the Early Tender Deadline and, accordingly, any Securities that were validly tendered may no longer be withdrawn except where additional withdrawal rights are required by law.

Title of

Security

CUSIP / ISIN Number

Principal

Amount 

Outstanding

Principal Amount

Tendered at Early

Tender Deadline

Percentage of

Outstanding

Securities Tendered

Total

Consideration

(1)(2)

11.125% Senior

Secured Notes 

due 2029

78573X AA8

U86042 AA3

US78573XAA81

USU86042AA34

$1,000,000,000.00

$ 930,682,000.00

93.07 %

$        $1,092.50

 

(1)

Dollars per $1,000 principal amount of Securities validly tendered and accepted for purchase.

(2)

Includes Early Tender Premium (as defined below). Does not include accrued and unpaid interest on the Securities, which will also be payable as provided herein.

The Tender Offer and Consent Solicitation remain subject to the satisfaction or waiver of the conditions described in the Offer to Purchase, including the financing for the Tender Offer and Consent Solicitation. Such conditions may be waived by Sabre Financial in its sole discretion, subject to applicable law. Any waiver of a condition by Sabre Financial will not constitute a waiver of any other condition. Subject to the satisfaction or waiver of such conditions and as described in the Offer to Purchase, Sabre Financial is expected to make payment on September 28, 2026 (such date and time, as it may be extended, the “Early Settlement Date”) for the Securities and related consents that (i) were validly tendered and delivered, as applicable, and not validly withdrawn or revoked, as applicable, at or prior to the Early Tender Deadline and (ii) are accepted for purchase on the Early Settlement Date.

The consideration to be paid for the Securities accepted for purchase on the Early Settlement Date per $1,000 principal amount of Securities is the amount set forth in the table above under the heading “Total Consideration.” The amounts set forth in the table above under “Total Consideration” include an early tender premium of $50 per $1,000 principal amount of Securities accepted for purchase (the “Early Tender Premium”). All Holders of Securities accepted for purchase will also receive accrued and unpaid interest from the most recent interest payment date preceding the Early Settlement Date to, but not including, the Early Settlement Date.

Any Holder who tenders Securities in the Tender Offer and Consent Solicitation will be deemed to automatically have provided consents, and Securities may not be tendered without delivering consents. Based on the consents received as of the Early Tender Deadline, Sabre Financial has obtained the required consents to effect all of the proposed amendments (the “Proposed Amendments”) as described in the Offer to Purchase. Consequently, as previously announced, Sabre Financial expects to execute a supplemental indenture (the “Supplemental Indenture”) effecting the Proposed Amendments with respect to the indenture dated December 5, 2025 (the “Indenture”), entered into by and among Sabre Financial, the guarantors party thereto, and Wilmington Trust, National Association, as trustee and collateral agent, under which the Securities were issued, and the Securities on or about the Early Settlement Date. The Supplemental Indenture will become effective upon (a) its execution and delivery by each of the parties thereto, and (b) the settlement of the Tender Offer with respect to accepted Securities tendered prior to the Early Tender Deadline on the Early Settlement Date.

In addition, pursuant to the terms of the Indenture, because more than 90% of the aggregate principal amount of the Securities outstanding has been validly tendered in the Tender Offer, Sabre Financial intends, following its purchase of the tendered Securities, to deliver a notice of redemption to redeem all Securities that remain outstanding after giving effect to the purchase of the Securities on the Early Settlement Date. The redemption price for such Securities will be equal to the Total Consideration set forth in the table above, plus accrued and unpaid interest thereon to, but excluding, the redemption date. The redemption date is expected to be October 13, 2026. Notwithstanding the foregoing, there can be no assurance that any Securities will be redeemed. Nothing herein shall constitute a notice of redemption with respect to the Securities.

Sabre Financial reserves the right, subject to applicable law, in its sole discretion, to waive any of the conditions of the Tender Offer or the Consent Solicitation, in whole or in part, at any time and from time to time. It also reserves the right, subject to applicable law, in its sole discretion, (1) to terminate or withdraw the Tender Offer or the Consent Solicitation at any time; (2) to extend the Early Tender Deadline, the Withdrawal Deadline or the Expiration Date; or (3) otherwise to amend the Tender Offer or Consent Solicitation in any respect. It may extend the Early Tender Deadline without extending the Withdrawal Deadline.

Information Relating to the Tender Offer and Consent Solicitation

The complete terms and conditions of the Tender Offer and Consent Solicitation are set forth in the Offer to Purchase. BofA Securities is the Dealer Manager and Solicitation Agent for the Tender Offer and Consent Solicitation. Investors with questions regarding the Tender Offer and Consent Solicitation may contact BofA Securities, collect: (980) 388-3646, toll-free: (888) 292-0070, email: debt_advisory@bofa.com. D.F. King & Co., Inc. is the tender and information agent for the Tender Offer and Consent Solicitation. Copies of the Offer to Purchase and any related offer documents may be obtained by contacting D.F. King & Co., Inc. by phone at (646) 455-1060 (New York) or (866) 356-7814 (toll-free) or by email at sabre@dfking.com. 

None of Sabre Financial, Sabre, their affiliates, their respective boards of directors and stockholders, the Dealer Manager and Solicitation Agent, the Tender Agent or Wilmington Trust, National Association, as trustee for the Securities, are making any recommendation as to whether Holders should tender any Securities or deliver any Consent in response to the Tender Offer and Consent Solicitation. Holders must make their own decision as to whether to tender any of their Securities and deliver their Consents, and, if so, the principal amount of Securities to tender and Consents to deliver.

This press release is for informational purposes only and is not an offer to buy or a solicitation of an offer to sell any of the Securities, and the Tender Offer and Consent Solicitation do not constitute offers to buy or the solicitation of offers to sell Securities in any jurisdiction or in any circumstances in which such offers are unlawful. The full details of the Tender Offer and Consent Solicitation, including complete instructions on how to tender Securities and deliver Consents, are included in the Offer to Purchase. Holders are strongly encouraged to read carefully the Offer to Purchase because it will contain important information.

Forward-Looking Statements

Certain statements herein are forward-looking statements about trends, future events, uncertainties and our plans and expectations of what may happen in the future. Any statements that are not historical or current facts are forward-looking statements. In many cases, you can identify forward-looking statements by terms such as “expect,” “guidance,” “outlook,” “trend,” “pro forma,” “on course,” “on track,” “target,” “potential,” “benefit,” “goal,” “believe,” “plan,” “confident,” “anticipate,” “indicate,” “trend,” “position,” “optimistic,” “will,” “forecast,” “continue,” “strategy,” “estimate,” “project,” “may,” “should,” “would,” “intend,” or the negative of these terms, where applicable, or other comparable terminology. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performances or achievements expressed or implied by the forward-looking statements. More information about potential risks and uncertainties that could materially affect our business and results of operations is included in the “Risk Factors” and “Forward-Looking Statements” sections in our Quarterly Report on Form 10-Q for the quarter ended June 30, 2026, filed with the SEC on August 6, 2026, our Annual Report on Form 10-K for the year ended December 31, 2025, filed with the SEC on February 18, 2026 and in our other filings with the SEC, as well as other risks and uncertainties specified in the “Certain Significant Considerations” section of the Offer to Purchase. We cannot guarantee future events, including financing of the Tender Offer and Consent Solicitation and successful completion of the Tender Offer and Consent Solicitation, outlook, guidance, results, actions, levels of activity, performance or achievements. Readers are cautioned not to place undue reliance on these forward-looking statements. Unless required by law, we undertake no obligation to publicly update or revise any forward-looking statements to reflect circumstances or events after the date they are made.

About Sabre

Powering the agentic revolution in travel. Sabre is an AI-native technology leader, backed by one of the world’s largest travel data clouds. With AI at its core and operating at unparalleled scale, Sabre transforms insights into innovation, empowering airlines, hoteliers, agencies and other partners to retail, distribute and fulfill travel worldwide. Sabre is built on an open, modular, cloud-native architecture and serves as the backbone for both established leaders and bold, new disruptors, guiding them to the next age of travel retailing through intelligent, connected, and personalized experiences.  

SABR-F

Contacts:

 

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/sabre-corporation-announces-early-tender-results-of-previously-announced-cash-tender-offer-and-consent-solicitation-by-sabre-financial-borrower-llc-302890677.html

SOURCE Sabre Corporation

Continue Reading

Technology

ATB Investment Management announces U.S. equity sub-advisor transition for Compass Portfolios and ATBIS U.S. Equity Pool

Published

on

By

EDMONTON, AB, Sept. 25, 2026 /CNW/ — ATB Investment Management Inc. today announced a sub-advisor transition to Boston Partners Global Investors, Inc.’s U.S. Large Cap Value Equity Strategy for the following funds (the “Funds”) from the Funds’ existing U.S. equities sub-advisor effective on or about October 15, 2026:

Compass Conservative PortfolioCompass Conservative Balanced PortfolioCompass Balanced PortfolioCompass Balanced Growth PortfolioCompass Growth PortfolioCompass Maximum Growth PortfolioATBIS U.S. Equity Pool

There are no changes to the investment objectives or investment strategies of the Funds.

Boston Partners Global Investors, Inc. (“Boston Partners”) is an institutional investment manager specializing in global value-equity strategies. Their clients include corporate and public pension plans, endowments, foundations, and high-net-worth individuals across major global markets. Boston Partners offers investment capabilities across U.S. and global and Non-US equities, long/short equities, and private wealth solutions. Boston Partners consists of 190 employees headquartered in Boston, with four other offices around the world. The firm manages nearly $150 billion USD as of June 30, 2026.

On September 28, 2026 a special distribution will be paid to unitholders with a record date of September 25, 2026, in relation to the appointment of Boston Partners. Information about the special distribution will be available on the ATB Investment Management website, at atbim.atb.com, on September 29, 2026.

About ATB Investment Management Inc.
ATB Investment Management Inc. (ATBIM), the asset management subsidiary of ATB Financial, provides a range of high-quality comprehensive investment management services and solutions. ATBIM’s offerings include: a range of mutual funds, including the Compass Portfolios, and tailored discretionary investment management for high-net-worth individuals and institutions. Established over 20 years ago and with over $25.2 billion in assets under management, ATBIM provides trusted expertise and a commitment to client success.

ATBIM is registered as a Portfolio Manager across various Canadian securities commissions with the Alberta Securities Commission (ASC) being its principal regulator. ATBIM is also registered as an Investment Fund Manager who manages the ATB Funds. ATBIM is a wholly owned subsidiary of ATB Financial and is a licensed user of the registered trademark ATB Wealth.

Commissions, trailing commissions, management fees and expenses all may be associated with mutual fund investments. Please read the prospectus before investing. Mutual funds are not guaranteed, their values change frequently and past performance may not be repeated.

About ATB Financial
Powering possibilities for our clients, communities, and beyond is what drives us at ATB Financial. As a leading Alberta-based financial institution with over $115 billion in total assets and assets under management, our success comes from more than 5,400 team members who deliver exceptional experiences to over 855,000 clients across our Personal and Business Banking, ATB Wealth Management, and ATB Cormark Capital Markets businesses. ATB Financial provides expert advice and services through our extensive branch network and agencies, our dedicated Client Care Centre and our digital banking options. ATB Financial is bronze certified as part of the Partnership Accreditation in Indigenous Relations commissioned by the Canadian Council for Indigenous Business. More information about ATB can be found at atb.com.

For more information or interview requests, please contact:
ATB Financial, Media Relations Team media@atb.com

SOURCE ATB Financial

Continue Reading

Technology

CGTN AMERICA & CCTV UN: Peng Liyuan, Melania Trump Visit National Museum of Asian Art

Published

on

By

Peng Liyuan, wife of Chinese President Xi Jinping, and Melania Trump, wife of US President Donald Trump, visited the National Museum of Asian Art in Washington, D.C., on Thursday, September 24.

WASHINGTON, Sept. 25, 2026 /PRNewswire-PRWeb/ — (This material is distributed by MediaLinks TV, LLC on behalf of CCTV. Additional information is available at the Department of Justice, Washington, D.C.)

CGTN America & CCTV UN releases “Peng Liyuan, Melania Trump Visit National Museum of Asian Art”

Peng Liyuan, wife of Chinese President Xi Jinping, and Melania Trump, wife of US President Donald Trump, visited the National Museum of Asian Art in Washington, D.C., on Thursday, September 24.

Peng and Melania visited exhibition halls including the Peacock Room. Peng expressed appreciation for the US side’s return of Chinese cultural relics to China on multiple occasions in recent years, expressing hope that China and the United States would continue to strengthen cooperation on cultural exchanges and cultural heritage protection and deepen the friendship between the two peoples.

After the tour, Peng and Melania watched American teenagers sing Chinese songs together and had cordial exchanges with them. Peng encouraged them to continue studying the Chinese language and culture and to become envoys of friendship between China and the United States.

The National Museum of Asian Art is a renowned US institution dedicated to the collection, research and exhibition of Asian art.

Media Contact

Sun, CGTN America, 1 2023931850, distribution@cgtnamerica.com

View original content:https://www.prweb.com/releases/cgtn-america–cctv-un-peng-liyuan-melania-trump-visit-national-museum-of-asian-art-302890609.html

SOURCE CGTN America

Continue Reading

Trending